RT Journal Article
SR Electronic
T1 Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a short communication
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.18.20105650
DO 10.1101/2020.05.18.20105650
A1 Laurent Chouchana
A1 Sana Boujaafar
A1 Ines Gana
A1 Laure-Hélène
A1 Lucile Regard
A1 Paul Legendre
A1 Celia Azoulay
A1 Etienne Canouï
A1 Jeremie Zerbit
A1 Nicolas Carlier
A1 Benjamin Terrier
A1 Solen Kernéis
A1 Rui Batista
A1 Jean-Marc Treluyer
A1 Yi Zheng
A1 Sihem Benaboud
YR 2020
UL http://medrxiv.org/content/early/2020/11/01/2020.05.18.20105650.abstract
AB Background Lopinavir/ritonavir has been proposed as off-label treatment for Covid-19, although efficacy have not been proven. It has previously been shown that lopinavir plasma concentration is dramatically increased in inflammatory settings. As Covid-19 may be associated with major inflammation, assessing lopinavir plasma concentration and its safety in Covid-19 patients is essential.Methods Real-world Covid-19 experience based on a retrospective study.Results Of 31 patients treated by lopinavir/ritonavir for Covid-19, we observed very high lopinavir plasma concentrations, increased of 4.6-fold (IQR, 3.6-6.2) with regards to average plasma concentrations in HIV. All except one patient were above the upper limit of the concentration ranges of HIV treatment. About one over four to five patients prematurely stopped treatment mainly secondary an adverse drug reaction related to hepatic or gastrointestinal disorders.Conclusion Lopinavir plasma concentrations in patients with moderate to severe Covid-19 were higher than expected, associated with the occurrence of hepatic or gastrointestinal adverse drug reactions. However, owing that high plasma concentration may be required for in vivo antiviral activity against SARS-CoV-2 as suggested by previous studies, it appears that, in the absence of adverse drug reaction, lopinavir dosage should not be reduced. Cautious is necessary as off-label use can be associated with a new drug safety profile.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been performed in accordance with the declaration of Helsinki and received approval by the Cochin Hospital Institutional Review Board (number 2020-08019)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request